How do these 3 diabetes agents compare in reducing mortality?
How do these 3 diabetes agents compare in reducing mortality? A meta-analysis reveals that there may be advantages associated with SGLT-2 inhibitors and GLP-1 agonists that are not associated with DPP-4 inhibitors. PRACTICE CHANGER: Consider adding a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a glucagon-like peptide 1 (GLP-1) agonist to the treatment regimen of patients with poorly controlled type 2 diabetes--especially those with higher CV rick. Doing so can reduce all-cause and cardiovascular (CV) mortality. STRENGTH OF RECOMMENDATION: B: BAsed on a network meta-analysis of 236 randomized controlled trials.
Journal of Family Practice, 68(2) 2019: 99-101.